Charles River Laboratories International, Inc. $CRL Shares Sold by Balefire LLC

Balefire LLC cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 27.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,833 shares of the medical research company’s stock after selling 3,661 shares during the quarter. Balefire LLC’s holdings in Charles River Laboratories International were worth $1,538,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CRL. Brooklyn Investment Group grew its position in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC grew its stake in shares of Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after buying an additional 152 shares during the period. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter worth approximately $29,000. Geneos Wealth Management Inc. grew its holdings in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. Finally, Allworth Financial LP lifted its holdings in shares of Charles River Laboratories International by 172.7% in the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after acquiring an additional 190 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $195.73 on Thursday. The stock’s 50-day moving average is $178.81 and its 200-day moving average is $164.72. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $200.58. The company has a market cap of $9.63 billion, a price-to-earnings ratio of -125.47, a price-to-earnings-growth ratio of 6.90 and a beta of 1.63.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The firm’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.59 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on CRL. JPMorgan Chase & Co. upped their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday. Baird R W raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Barclays lifted their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday. Finally, Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and boosted their target price for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $194.07.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).